## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently Amended) A nucleic acid vector for the expression of at least two cistrons comprising:
- a. a promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
- a nucleotide sequence that provides IRES activity operably linked to each b. cistron subsequent to the first cistron, wherein at least one of the nucleotide sequences that provide IRES activity comprises a nucleotide sequence chosen from: a nucleotide sequence comprising SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 1-215 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 45-239 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 45-215 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 1-74 and 187-239 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 1-74 and 187-215 of SEQ ID NO. 1; a nucleotide sequence that differs from a nucleotide sequence comprising SEQ ID NO. 1 by substitution of the nucleotides at positions 124-127 of SEQ ID NO. 1; a nucleotide sequence comprising SEQ ID NO. 2; a nucleotide sequence that differs from a nucleotide sequence comprising SEQ

Application No. 10/614,282 Attorney Docket No. 8842.0001

a nucleotide sequence that differs from a nucleotide sequence comprising SEQ ID NO. 2 by substitution of the nucleotides at positions 126-129 of SEQ ID NO. 2 at least one nucleotide sequence comprising SEQ ID NO. 1, or a fragment thereof operably linked to at least one of said at least two cistrons, wherein said nucleotide sequence comprising SEQ ID NO. 1, or fragment thereof, provides IRES activity.

- 2. (Previously Presented) The nucleic acid vector of claim 1, wherein at least one of said at least two cistrons comprises a reporter gene.
- 3. (Previously Presented) The nucleic acid vector of claim 1, wherein at least one of said at least two cistrons comprises a therapeutic gene.
- 4. (Previously Presented) A biological vector capable of expressing at least two cistrons comprising the nucleic acid vector of claim 1.
- 5. (Previously Presented) The biological vector of claim 4, wherein said biological vector is selected from poxvirus, adenovirus, herpesvirus, adeno-associated virus, retrovirus, and baculovirus.
- 6-11. (Canceled)
- 12. (Previously Presented) A host cell comprising the nucleic acid vector of claim 1.
- 13. (Previously Presented) The host cell of claim 12, wherein said host cell is an insect cell.

14. (Previously Presented) The host cell of claim 13, wherein said insect cell is a Drosophila cell. 15-16. (Canceled) (Currently Amended) A method for expressing at least two cistrons comprising: 17. introducing into a host cell a nucleic acid vector comprising: a promoter operably linked to a nucleotide sequence comprising at least a. two cistrons: and b. a nucleotide sequence that provides IRES activity operably linked to each cistron subsequent to the first cistron, wherein at least one of the nucleotide sequences that provide IRES activity comprises a nucleotide sequence chosen from: a nucleotide sequence comprising SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 1-215 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 45-239 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 45-215 of SEQ ID NO. 1; a nucleotide sequence comprising nucleotides 1-74 and 187-239 of SEQ ID NO. <u>1;</u> a nucleotide sequence comprising nucleotides 1-74 and 187-215 of SEQ ID NO. <u>1;</u> a nucleotide sequence that differs from a nucleotide sequence comprising SEQ ID NO. 1 by substitution of the nucleotides at positions 124-127 of SEQ ID NO. 1; a nucleotide sequence comprising SEQ ID NO. 2;

a nucleotide sequence that differs from a nucleotide sequence comprising SEQ

ID NO. 2 by substitution of the nucleotides at positions 136-139 of SEQ ID NO. 2; and
a nucleotide sequence that differs from a nucleotide sequence comprising SEQ
ID NO. 2 by substitution of the nucleotides at positions 126-129 of SEQ ID NO. 2-at-
least one nucleotide sequence comprising SEQ ID NO. 1, or a fragment thereof
operably linked to at least one of said at least two cistrons, wherein said nucleotide
sequence comprising SEQ ID NO. 1, or fragment thereof, provides IRES activity.
18-19. (Canceled)
20. (Currently Amended) A baculovirus transfer vector for the expression of at least
two cistrons comprising:
a. a polyhedrin promoter operably linked to a nucleotide sequence
comprising at least two cistrons; and
b. <u>a nucleotide sequence that provides IRES activity operably linked to each</u>
cistron subsequent to the first cistron, wherein at least one of the nucleotide sequences
that provide IRES activity comprises a nucleotide sequence chosen from:
a nucleotide sequence comprising SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 1-215 of SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 45-239 of SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 45-215 of SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 1-74 and 187-239 of SEQ ID NO.
<u>1:</u>
a nucleotide sequence comprising nucleotides 1-74 and 187-215 of SEQ ID NO.

<u>1;</u>

Application No. 10/614,282 Attorney Docket No. 8842.0001

a nucleotide sequence that differs from a nucleotide sequence comprising SEQ ID NO. 1 by substitution of the nucleotides at positions 124-127 of SEQ ID NO. 1;

a nucleotide sequence comprising SEQ ID NO. 2;

a nucleotide sequence that differs from a nucleotide sequence comprising SEQ ID NO. 2 by substitution of the nucleotides at positions 136-139 of SEQ ID NO. 2; and a nucleotide sequence that differs from a nucleotide sequence comprising SEQ ID NO. 2 by substitution of the nucleotides at positions 126-129 of SEQ ID NO. 2 at least one nucleotide sequence comprising SEQ ID NO. 1, or a fragment thereof, operably linked to at least one of said at least two cistrons, wherein said nucleotide sequence comprising SEQ ID NO. 1, or fragment thereof provides IRES activity.

- 21. (Previously Presented) The baculovirus transfer vector of claim 20, wherein at least one of at least two cistrons comprises a reporter gene.
- 22. (Previously Presented) The baculovirus transfer vector of claim 20, wherein at least one of at least two cistrons comprises a therapeutic gene.
- 23. (Currently Amended) A recombinant baculovirus capable of expressing at least two cistrons in a host cell comprising a baculovirus genome comprising:
- a. a polyhedrin promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
- b. <u>a nucleotide sequence that provides IRES activity operably linked to each</u>

  <u>cistron subsequent to the first cistron, wherein at least one of the nucleotide sequences</u>

  <u>that provide IRES activity comprises a nucleotide sequence chosen from:</u>

a nucleotide sequence comprising SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 1-215 of SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 45-239 of SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 45-215 of SEQ ID NO. 1;
a nucleotide sequence comprising nucleotides 1-74 and 187-239 of SEQ ID NO.
<u>1</u> ;
a nucleotide sequence comprising nucleotides 1-74 and 187-215 of SEQ ID NO.
<u>1</u> ;
a nucleotide sequence that differs from a nucleotide sequence comprising SEQ
ID NO. 1 by substitution of the nucleotides at positions 124-127 of SEQ ID NO. 1;
a nucleotide sequence comprising SEQ ID NO. 2;
a nucleotide sequence that differs from a nucleotide sequence comprising SEQ
ID NO. 2 by substitution of the nucleotides at positions 136-139 of SEQ ID NO. 2; and
a nucleotide sequence that differs from a nucleotide sequence comprising SEQ
ID NO. 2 by substitution of the nucleotides at positions 126-129 of SEQ ID NO. 2-at-
least one nucleotide sequence comprising SEQ ID NO. 1, or a fragment thereof-
operably linked to at least one of said at least two cistrons, wherein said nucleotide
sequence comprising SEQ ID NO. 1, or fragment thereof, provides IRES activity.
24 (Description Description) A most bod for some description of the set by
24. (Previously Presented) A method for producing a recombinant baculovirus

introducing a baculovirus transfer vector of claim 20 and a baculovirus

capable of expressing at least two cistrons comprising:

a.

Application No. 10/614,282 Attorney Docket No. 8842.0001

and

- b. isolating a recombinant baculovirus.
- 25. (Previously Presented) The method of claim 24, wherein said recombinant baculovirus is isolated by selecting plaques expressing at least one of said at least two cistrons.
- 26. (Previously Presented) A baculovirus host cell expressing at least two cistrons comprising the recombinant baculovirus of claim 23.

27-35. (Canceled)

- 36. (Withdrawn) A method of treating a patient comprising administering the nucleic acid vector of claim 1.
- 37. (Withdrawn) A method of treating a patient comprising administering the biological vector of claim 4.
- 38. (Withdrawn) A method of treating a patient comprising:
  - a. excising a cell or tissue from said patient;
- b. introducing the nucleic acid vector of claim 1 into said excised cell or tissue; and
  - c. reimplanting said cell or tissue into said patient.
- 39. (Withdrawn) A method of treating a patient comprising:
  - a. excising a cell or tissue from said patient;
  - b. introducing the biological vector of claim 4 into said excised cell or tissue;

and

Ý

c. reimplanting said cell or tissue into said patient.

40-53. (Canceled)